Omecamtiv mecarbil
Omecamtiv mecarbil
Omecamtiv mecarbil
Omecamtiv mecarbil
Omecamtiv mecarbil
Amgen, Cytokinetics expand collaboration
Thursday, June 13, 2013 01:30 PM
Amgen and Cytokinetics,
a clinical-stage biopharmaceutical company, have expanded their
strategic collaboration to include Japan. In 2006, Cytokinetics and
Amgen entered into a collaboration to discover, develop and
commercialize novel small-molecule therapeutics that activate cardiac
muscle contractility for potential applications in the treatment of
heart failure. Omecamtiv mecarbil is the most advanced drug candidate in
this collaboration.
http://www.centerwatch.com//news-online/article/4852/amgen-cytokinetics-expand-collaboration
Omecamtiv mecarbil , previously codenamed CK-1827452, is a cardiac specific myosin activator. It is clinically tested for its role in the treatment of left ventricular systolic heart failure. Systolic heart failure is characterised as a decreased cardiac output (<40% ejection fraction), due to decreased stroke volume, resulting in the inability to meet the metabolic demands of the body. The loss of contraction is caused by a reduced number of effective actin-myosin cross bridges in the left ventricular myocytes. One possible underlying mechanism is altered signal transduction that interferes with excitation-contraction coupling. A decreased cardiac output causes peripheral hypotension and activation of the sympathetic nervous system. This in turn stimulates the cardiac myocytes excessively, eventually leading to left ventricular hypertrophy, characteristic of chronic heart failure. Some symptoms of systolic heart failure are fatigue, peripheral oedema, dyspnoea, exercise intolerance and breathlessness. Current inotropic drug therapies such as dobutamine, are palliative and not a cure. They also cause many adverse effects including arrhythmias related to increased myocardical oxygen consumption, desensitization of adrenergic receptors and altering intracellular calcium levels. Thus systolic heart failure is considered malignant, however the novel mechanism of Omecamtiv Mecarbil is a hopeful long-term resolution.
Amgen, Cytokinetics expand collaboration
Thursday, June 13, 2013 01:30 PM
Amgen and Cytokinetics,
a clinical-stage biopharmaceutical company, have expanded their
strategic collaboration to include Japan. In 2006, Cytokinetics and
Amgen entered into a collaboration to discover, develop and
commercialize novel small-molecule therapeutics that activate cardiac
muscle contractility for potential applications in the treatment of
heart failure. Omecamtiv mecarbil is the most advanced drug candidate in
this collaboration.
No comments:
Post a Comment